BridgeBio Pharma to Present Additional Data from the Phase 3 ATTRibute-CM Study in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the American Heart Association (AHA) Scientific Sessions 2023
09 November 2023 - 11:30PM
BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the
“Company”), a commercial-stage biopharmaceutical company
focused on genetic diseases and cancers, announced today that
additional Phase 3 data on clinical outcomes from ATTRibute-CM, its
study of acoramidis in ATTR-CM will be presented at the AHA
Scientific Sessions 2023, taking place in Philadelphia,
Pennsylvania on November 11 - 13, 2023. As previously announced, a
highly statistically significant result was observed on the primary
endpoint of ATTRibute-CM with a Win Ratio of 1.8 (p<0.0001).
ATTRibute-CM was designed to study the efficacy and safety of
acoramidis, an investigational, next-generation,
orally-administered, highly potent, small molecule stabilizer of
transthyretin.
BridgeBio will host an investor call with members of the
Company’s leadership team on Sunday, November 12 at 11:15 am ET to
discuss the results shared at the meeting.
Oral presentation details:
Acoramidis Improves Clinical Outcomes in Transthyretin
Amyloid Cardiomyopathy PatientsPresenter:
Dr. Daniel Judge, Professor of Medicine and Cardiology at the
Medical University of South Carolina, and Co-Chair of the
ATTRibute-CM Steering CommitteeDate/time: Sunday,
November 12 at 10:19 am ETLocation: Room 203AB,
Pennsylvania Convention Center
Webcast InformationBridgeBio will host an
investor call and simultaneous webcast to discuss the additional
data presented at AHA 2023 for the ATTRibute-CM Phase 3 trial on
Sunday, November 12 at 11:15 am ET. A link to the webcast may be
accessed from the event calendar page of BridgeBio’s website at
https://investor.bridgebio.com/.
A replay of the conference call and webcast will be archived on the
Company’s website and will be available for at least 30 days
following the event.
About BridgeBio Pharma, Inc.BridgeBio Pharma
Inc. (BridgeBio) is a commercial-stage biopharmaceutical company
founded to discover, create, test and deliver transformative
medicines to treat patients who suffer from genetic diseases and
cancers with clear genetic drivers. BridgeBio’s pipeline of
development programs ranges from early science to advanced clinical
trials. BridgeBio was founded in 2015 and its team of experienced
drug discoverers, developers, and innovators are committed to
applying advances in genetic medicine to help patients as quickly
as possible. For more information
visit bridgebio.com and follow us
on LinkedIn and Twitter.
BridgeBio Media Contact:Vikram
Balicontact@bridgebio.com (650)-789-8220
BridgeBio Pharma (NASDAQ:BBIO)
Historical Stock Chart
From Apr 2024 to May 2024
BridgeBio Pharma (NASDAQ:BBIO)
Historical Stock Chart
From May 2023 to May 2024